

Financial Report

2023

SAKK in Figures



1 network

made up of 22 regular members, one associate member, eight phase I sites, 15 research partners, 22 industry partners, 17 authorities and foundations eight partner organizations

20

specialized bodies

working in project groups, working groups and sections

499

patients

we would like to thank for participating in our trials in 2023

25

open clinical trials

researching effective and well tolerated new cancer therapies and better treatments



79 employees

working in the Group's Competence Center

39

scientific articles

published by oncologists and hematologists in scientific journals



5 awards

were presented to researchers by us in conjunction with our industry partners

10

Patient Advisory Board members

contributing the perspective of people living with cancer to our strategy, communications, trial development and trial conduct

9

mentees

of the Young Oncology Academy took part in SAKK's support and mentoring program

Contents

Goals

Editorial by the President 4

Together

Editorial by the CFO 5

Our Donors 6

Promoting Dialog 7

Organization Chart 8

Financial Statements

Balance Sheet 9

Statement of Operations 10

Cash Flow Statement 11

Statement of Changes in Capital 12

Statement of Changes in Funds 13

Annex

Notes to the 2023 Annual Financial Statements 14

Auditor's Report 17

Publishing Details 19



Annual Portrait

The Financial Report is published as an addendum to the Annual Portrait. This reports on the events of 2023 and provides an insight into SAKK's activities.

A Solid Foundation for a Successful Future

2023 was a good year for SAKK from a financial perspective too. Despite investing more than one million Swiss francs, SAKK was able to report a small profit. This is a sound basis for continued financial health and enabling more people to benefit from the valuable results of clinical research.

SAKK's financial performance in 2023 was stronger than expected, and we were able to close the year CHF 50,000 better off than budgeted. We achieved this despite having invested one million francs in the SAKK Trial Award. This success would not have been possible without the dedicated work of our Competence Center team. The entire Board would like to offer them its sincerest thanks, as would I.

We also wish to thank the State Secretariat for Education, Research and Innovation (SERI) for its ongoing financial support. Thanks also go to Swiss Cancer Research, the Rising Tide Foundation, the Swiss National Science Foundation and many more. Finally, we would like to express our gratitude to our partners in the pharmaceutical industry. We offer special thanks to the Swiss Foundation for Clinical Cancer Research (SSKK) and its president Norbert Hochreutener. SSKK has been a steadfast supporter of SAKK for decades, and many important research projects would not have been possible without it. Since the foundation's funds have been exhausted, it is sadly due to be wound up during 2024.

The outlook for 2024 is optimistic. We can even expect a small profit. Nevertheless, it is important to step up our efforts in respect of our financial situation. For example, we were unable to activate a sufficient number of new trials in 2023. Failure to initiate additional new trials will have a negative financial impact in 2025.

The Scientific Committee approved 16 trials in 2023, all of which will be launched in 2024. This is cause for optimism. With the energetic support of the Competence Center, our project groups were able to submit a record number of grant applications in 2023. Seven of these went to the Swiss National Science Foundation. The Competence Center will step up its efforts to secure new sources of funding in 2024 and, as part of a pilot project, we are also working on ways of simplifying Competence Center processes and improving their efficiency. This should enable us to provide more resources for new research projects.

SAKK is a unique and important organization for cancer patients in Switzerland. Given the current global political situation, securing reliable financing for SAKK is an important, but

not straightforward, challenge. Our aim is to remain financially healthy and significantly increase our patient numbers over the years ahead. By doing so, we can make the medical options of tomorrow available to more people, improve their quality of life and drive forward research.

Prof. Dr. med. Miklos Pless, Board President



A Positive Result for the Second Year in Succession

Clinical cancer research demands endurance and significant financial resources. With 17 new trials and a second positive result that came in ahead of budget in a row, 2023 was a successful year. This was thanks in part to the Network Trial Award.

Mr Tschofen, what is the Network Trial Award?

Jürg Tschofen: The Network Trial Award was first introduced in 2022, and a second one took place in 2023. The scheme involves SAKK offering prize money of CHF 1,000,000 to fund a trial. SAKK's Scientific Committee carries out an initial assessment of the trials that are submitted, considering whether they represent a significant improvement for patients in terms of science, treatment and chances of a cure. The winner is chosen by an independent jury. We're already excited to see which trial will win this time.

Why is the Network Trial Award so important?

Jürg Tschofen: The award enables SAKK to demonstrate that it can act as a trial funder again. No less than 18 trials were submitted for the last award in 2022. And one of them was lucky enough to receive the CHF 1,000,000 prize. In the end, however, everyone who took part was a winner, since SAKK was able to progress and implement a good number of the remaining 17 trials.

What does that mean for SAKK?

Jürg Tschofen: It means that SAKK can play a role for the network in a large number of areas, say in trial development, data management, clinical project management and statistics. The role also extends to managing relations with Swissmedic and ethics committees, to monitoring and to funding provision.

What impact do you hope it will have?

Jürg Tschofen: That the network will be able to conduct more studies with SAKK instead of having to rely primarily on the generous payments available from the industry. Working with SAKK gives principal investigators a certain amount of autonomy, nationwide coverage and a one-stop shop for our partners.

What is your personal assessment of 2023?

Jürg Tschofen: I'm pleased that we ended the year ahead of budget, which means we made a small profit, and with a sound balance sheet. And that we did so without a single franc of outside funding.



|| SAKK can play a role for the network in a large number of areas.

Jürg Tschofen, CFO

Our Donors

Public sector and third parties

Alfred und Anneliese Sutter-Stöttner Stiftung
 Hedy Glor-Meyer Stiftung
 Klinikum der Universität München
 Norges teknisk-naturvitenskapelige universitet NTNU
 Rising Tide Foundation for Clinical Cancer Research
 Swiss Paediatric Oncology Group SPOG
 Swiss Foundation for Clinical Cancer Research SSKK
 SOHC Board of Trustees Swiss Oncology & Hematology
 SONK
 State Secretariat for Education, Research and Innovation
 SERI
 Swiss Cancer Research Foundation
 University of Bern
 University of Zurich

Industry

AbbVie AG
 Advanced Accelerator Applications International SA
 Amgen Switzerland AG
 Astellas Pharma AG
 AstraZeneca AG
 Bayer Healthcare Pharmaceutical, Pittsburgh, USA
 Bayer (Schweiz) AG, Zurich
 BeiGene Switzerland GmbH
 Bilthoven Biologicals B.V.
 Bristol-Myers Squibb SA
 Celgene International Sàrl
 Daiichi Sankyo (Schweiz) AG
 Eli Lilly (Suisse) SA
 Fédération Francophone de Cancérologie Digestive FFCD
 Genetica AG
 Gilead Sciences Switzerland Sàrl
 GlaxoSmithKline AG

Helvepharm AG
 IDEOGEN AG
 Immunophotonics Inc.
 Incyte Biosciences International Sàrl
 InnoMedica Schweiz AG
 IPSEN Pharma Schweiz GmbH
 Janssen-Cilag AG
 Janssen Pharmaceutica NV
 MaxiVAX S.A.
 Merck (Schweiz) AG
 MSD Merck Sharp & Dohme AG
 Myriad Genetics GmbH
 Novartis Pharma Schweiz AG
 Pfizer AG
 Pharma Mar SA
 Pierre Fabre Pharma AG
 Release Therapeutics
 Roche Pharma (Schweiz) AG
 Sanofi-Aventis (Schweiz) AG
 Seagen International GmbH
 Servier (Suisse) S.A.
 Stemline Therapeutics Switzerland GmbH
 Takeda Pharma AG
 Vivesto AB

International research groups

ABCSG Research Services GmbH
 AGO Research GmbH
 Deutsche CLL Studiengruppe DCLLSG
 ETOP IBCSG Partners Foundation
 European Organisation for Research and Treatment
 of Cancer (AISBL/IVZW) EORTC
 Exact Sciences International GmbH
 GHSG Studienzentrale

HOVON Stichting
 International Extranodal Lymphoma Study Group (IELSG)
 IRCCS – Istituto di Ricerche Farmacologiche Mario Negri
 Serum Institute of India Private Ltd.
 St. Clara Forschung AG

Additional donations from our members

Lausanne University Hospital (CHUV)
 Ente Ospedaliero Cantonale
 Hôpital du Valais
 Geneva University Hospitals (HUG)
 Insel Gruppe AG
 Oncology Institute of Southern Switzerland (IOSI)
 Cantonal Hospital Aarau AG
 Cantonal Hospital Baden AG
 Cantonal Hospital Fribourg HFR
 Cantonal Hospital Graubünden
 Cantonal Hospital St. Gallen
 Cantonal Hospital Winterthur
 Landeskrankenhaus Feldkirch
 LUKS Spitalbetriebe AG
 Onkozentrum Zurich
 Réseau Hospitalier Neuchâtelois (RHNe)
 Solothurner Spitäler AG
 Spital STS AG Thun
 Spital Thurgau AG
 Spitalzentrum Biel AG
 Stadtspital Zurich Triemli
 University Hospital Basel
 University Hospital Zurich
 University of Geneva

Promoting dialog

SAKK promotes the development of effective cancer treatments through collaboration and initiatives such as training courses, events and symposiums as a way of opening up fresh perspectives on treatment.

Participants at meetings held in parallel to ESMO, AACR and ASH discussed new approaches to cancer research. Introductory courses in Lausanne and St. Gallen developed participants' understanding of genetic counseling in oncology. At the Semi-Annual Meeting in November, SAKK joined with partners to present five awards. The Patient Advisory Board's involvement in various events is particularly valuable. Read the interview on this subject on page 10 of our Annual Portrait.

January 14, 2023
GU Cancer Forum
 Zurich

January 19, 2023
GU Cancer Forum
 Lausanne

January 19, 2023
SAKK Online secuTrial® Training Course for CRCs and CTNs
 Online

January 26, 2023
SAKK Online secuTrial® Training Course for CRCs and CTNs
 Online

January 26, 2023
SAKK Training Course for CRCs and CTNs
 Bern

February 24–25, 2023
Introductory Course in Genetic Counseling in Oncology
 St. Gallen

March 15, 2023
Scientific Advisory Board
 Zurich

March 22, 2023
GU Cancer Forum
 Lugano

March 23 & 30, 2023
SAKK Investigators' Education
 Bern

May 11, 2023
PostAACR
 Bern

May 11–12, 2023
SAKK Semi-Annual Meeting
 Bern

May 12, 2023
SAKK Patient Advisory Board: How to implement partnerships with patient experts in clinical research?
 Bern

June 07–10, 2023
Chicago in the Mountains
 Flüeli-Ranft

June 15, 2023
SAKK Online secuTrial® Training Course for CRCs and CTNs
 Online

August 28, 2023
Industry Pool Meeting
 Bern

August 31, 2023
SAKK Training Course for CRCs and CTNs
 Bern

September 07, 2023
SAKK Online secuTrial® Training Course for CRCs and CTNs
 Online

September 08–09, 2023
Introductory Course in Genetic Counseling in Oncology – English
 Lugano

September 14–15, 2023
Translational Urogenital Cancer Networking Meeting
 Bern


October 12, 2023
SAKK Patient Advisory Board: Patient Forum "Of Mice and Men"
 Bern

October 26, 2023
ESMO in the Alps
 Lucerne

November 22–24, 2023
SOHC/SAKK Semi-Annual Meeting
 Basel

Organization Chart

SAKK



Balance Sheet

As at December 31
in CHF

	Annex	2023	2022	
Assets				
Cash and cash equivalents		9,825,861	11,853,908	
Accounts receivable	1)	1,433,782	1,523,100	
Other accounts receivable		68,973	176,016	
Prepaid expenses and accrued income	2)	650,686	1,308,009	
Total current assets		11,979,302	14,861,033	48.5%
Financial assets	3)	20,801,398	15,769,848	
Total fixed assets		20,801,398	15,769,848	63.5%
Total assets		32,780,700	30,630,881	51.5%

As at December 31
in CHF

	Annex	2023	2022	
Liabilities				
Accounts payable	4)	2,069,126	1,549,363	
Other accounts payable		–	425,777	
Accrued liabilities and deferred income	5)	16,901,190	15,827,814	
Total short-term liabilities		18,970,315	17,802,955	58.1%
Other provisions		251,036	0	
Total long-term liabilities		251,036	0	0.0%
"Education Grant" fund		–	35,000	
"Special purpose" fund		270,932	217,932	
"Hubacher" fund		9,429,490	8,806,449	
Total special purpose fund capital		9,700,422	9,059,382	29.6%
Organizational capital				
Free capital as at January 01		3,768,544	3,419,771	
Group result		90,383	348,773	
Free capital as at December 31		3,858,927	3,768,544	
Total organizational capital		3,858,927	3,768,544	12.3%
Total liabilities		32,780,700	30,630,881	100.0%

Statement of Operations

January 01 to December 31
in CHF

	Annex	2023	2022	
Operating income				
Research contributions SERI		5,805,172	5,830,628	
Research contributions KLS		-57,400	118,900	
Research contributions KFS		1,043,878	1,326,811	
Research contributions SSKK		128,500	100,000	
Research contributions, third parties		164,255	676,819	
Research contributions, Swiss health insurers		1,785,348	1,811,281	
Income from industry partnerships		4,309,408	3,952,784	
Income from foreign trial groups		565,484	771,281	
Income from Cancer Bulletin		-	-	
Income from Patient Advisory Board		54,097	52,115	
Donations, bequests, legacies		236,727	159,614	
Miscellaneous income		1,608,639	2,046,446	
Losses on receivables		61,189	87,195	
Total operating income		15,705,297	16,933,875	100.0%
Operating costs				
Miscellaneous trial-related expenses		-1,051,446	-1,292,567	
Research contributions IBCSG/ETOP		-	-	
Research contributions, sites		-3,185,436	-3,161,808	
Events, congresses and hospitality expenses		-1,330,209	-1,306,096	
Other operating expenses		108,959	-103,384	
Total operating expenses		-5,458,132	-5,863,856	-34.6%
Interim result 1		10,247,166	11,070,019	65.4%

January 01 to December 31
in CHF

	Annex	2023	2022	
Coordination expenses				
Personnel expenses	6)	-8,683,797	-8,273,627	
Other coordination expenses		-1,439,013	-1,593,015	
Advertising expenses		-366,339	-53,404	
Total coordination expenses		-10,489,149	-9,920,046	-58.6%
Interim result 2		-241,983	1,149,973	6.8%
Financial result				
Financial income		590,284	189,201	
Financial expenses		-257,918	-1,432,480	
Total financial result		332,366	-1,243,279	-7.3%
Interim result 3		90,383	-93,306	-0.6%
Out-of-period result				
Out-of-period income		-	442,079	
Out-of-period expenses		-	-	
Total out-of-period result		-	442,079	2.6%
Annual result		90,383	348,773	2.1%

Cash Flow Statement

January 01 to December 31

in CHF

	2023	2022
+/- Annual gain (+) / loss (-)	90,383	348,773
+/- Depreciation/value adjustments (+) and additions (-) to fixed assets / appreciation	-5,031,550	2,595,100
+/- Recognition (+) and reversal (-) of provisions	251,036	-
+/- Depreciation (+) and appreciation (-) of listed short-term assets	-	-
+/- Decrease (+) / increase (-) in short-term receivables	196,361	1,395,965
+/- Decrease (+) / increase (-) in prepaid expenses	657,323	-585,606
+/- Increase (+) / decrease (-) in short-term liabilities	93,985	-406,144
+/- Increase (+) / decrease (-) in deferred income	1,073,375	128,959
+/- Other cash flow-neutral expenses (+) and income (-)	641,040	-1,375,204
= Cash flow from operating activities	-2,028,046	2,101,844
- Investments in financial assets	-	-
+ Divestment of financial assets	-	-
= Cash flow from investing activities	-	-
+/- Assumption (+) / repayment (-) of short- and long-term financial liabilities	-	-
+/- Capital increases (+) / repayments (-)	-	-
= Cash flow from financing activities	-	-
Increase or decrease in cash and cash equivalents	-2,028,046	2,101,844

January 01 to December 31

in CHF

	2023	2022
Change in cash and cash equivalents		
As at start of reporting year	11,853,908	9,752,064
As at end of reporting year	9,825,861	11,853,908
Increase (+) / decrease (-) in cash and cash equivalents	-2,028,046	2,101,844

Statement of Changes in Capital

In CHF	Free capital	Net profit (+) Net loss (-)	Value fluctuation reserve Securities	Total
2023				
Holding January 01, 2023	3,768,544	-	-	3,768,544
Change in reserves	-	-	-	-
Annual result	90,383	-	-	90,383
Holding December 31, 2023	3,858,927	-	-	3,858,927
2022				
Holding January 01, 2022	3,419,771	-	-	3,419,771
Change in reserves	-	-	-	-
Annual result	348,773	-	-	348,773
Holding December 31, 2022	3,768,544	-	-	3,768,544

Statement of Changes in Funds

In CHF	"Education Grant" fund ¹	"Special purpose" fund ²	"Hubacher" fund	Total
2023				
Holding January 01, 2023	35,000	217,932	8,806,449	9,059,382
Fund creation	–	53,000	–	18,000
Fund income	–	–	–	–
Fund value adjustment	–	–	623,040	623,040
Fund costs	–	–	–	–
Fund use	–35,000	–	–	–
Holding December 31, 2023	–	270,932	9,429,490	9,700,422

In CHF	"Education Grant" fund ¹	"Special purpose" fund ²	"Hubacher" fund	Total
2022				
Holding January 01, 2022	–	217,932	10,216,653	10,434,586
Fund creation	35,000	–	–	35,000
Fund income	–	–	–1,400,418	–1,400,418
Fund costs	–	–	–9,786	–9,786
Fund use	–	–	–	–
Holding December 31, 2022	35,000	217,932	8,806,449	9,059,382

¹ Fund for Janssen-Cilag AG research grant.

² Fund for non-industry-associated clinical trials, translational research and training of research specialists.

³ Fund from the bequest of Dr. Margaretha Hubacher specifically for non-Hodgkin lymphoma research.

Notes to the 2023 Annual Financial Statements

SAKK is an association based in Bern. These annual financial statements have been prepared in accordance with the requirements of Swiss law, in particular the articles on commercial accounting and financial reporting in the Swiss Code of Obligations (Art. 957 to 962).

As at December 31

Headcount

	2023	2022
Bandwidth of full-time equivalents (average for year)	> 50 to 250	> 50 to 250

As at December 31 in CHF

Disclosures on, breakdown of and commentary on items in the balance sheet and income statement

1 Accounts receivable

Accounts receivable are generally carried at their nominal amount less specific valuation allowances. A general valuation allowance is recognized for the remainder.

Outstanding accounts receivable gross	1,552,671	1,704,180
Allowance for doubtful accounts	118,889	181,080

Net accounts receivable **1,433,782** **1,523,100**

2 Prepaid expenses and accrued income

Prepaid expenses and accrued income consist mainly of:

Accrued income for trial SAKK 96/12	625,332	1,218,308
-------------------------------------	---------	-----------

As at December 31 in CHF

3 Financial assets

	20,801,398	15,769,848
Of which securities Hubacher fund	9,390,375	8,803,263

Financial assets are carried at their current market value. The SAKK investment rules were taken into account when investing. Fixed assets are managed externally by Swiss banks.

4 Accounts payable

Accounts payable are carried at their nominal amount.

5 Accrued liabilities and deferred income

Accrued liabilities and deferred income are made up mainly of the following items:

Contributions SAKK 96/12	447,179	465,318
Compensation, sites SAKK 96/12	168,253	357,892
Future payments	1,163,334	1,505,160
Ongoing trial accruals and deferrals	11,998,998	11,017,183

Trial accruals and deferrals comprise all active trials which, according to cost center accounting, show an amount of pre-financing or a profit. The trial accruals and deferrals were recognized as liabilities in order to cover measurement risks. The other accruals and deferrals are general accruals/deferrals to ensure that income and expenses are recognized appropriately in the period in which they arise.

January 01 to December 31 in CHF	2023	2022
----------------------------------	------	------

6 Personnel expenses

Gross salaries	7,268,009	6,770,019
Third-party salaries	62,841	203,058
Social insurance	1,224,601	1,139,196
Other personnel expenses	180,695	161,353
Personnel expenses	8,736,146	8,273,627

Auditors' fee

Fee for auditing services	31,000	30,000
Fee for other services	-	-

January 01 to December 31 in CHF	2023	2022
----------------------------------	------	------

Remainder of liabilities from purchase contract-type leasing transactions and other leasing liabilities not maturing or called within 12 months after the balance sheet date.

Total non-capitalized leasing liabilities	488,907	697,983
Liabilities to pension institutions	1,955	0

January 01 to December 31 in CHF	2023	2022
----------------------------------	------	------

Notes on extraordinary, non-recurring or out-of-period items in the income statement

Total out-of-period expenses	-	-
2022: Write-back of trial risks	-	342,079
Write-back, 2022: TP, restructuring	-	100,000
Total out-of-period income	-	442,079
Total out-of-period result	-	442,079

Cost reductions as a result of the restructuring are included here.

Net release of hidden reserves	-	-
---------------------------------------	---	---

Events after the balance sheet date: none

Measurement of research projects:

For the 2023 annual financial statements, research projects were measured in accordance with the principle of itemized measurement for long-term research projects, comprising identifiable losses on individual trials through to 2029 (measurement at the lower of cost or market value). Any losses incurred after this period are not included since management assumes that additional financing has to be generated for such projects and funding requirements per trial are significantly lower at the long end.

Measurement was based on the rolling planning for 2024 to 2029 prepared by the responsible project managers, which takes account of likely project financing, external and internal trial costs and internal hours less any withdrawals from funds. In addition, the approved, anticipated and non-ring-fenced federal financial contribution for the 2025 to 2029 period has been offset by the sum total for budgeted personnel hours and external costs incurred by loss-making projects, less project financing. SAKK assumes that funding from the next SERI financing round for 2025–28 will be the same.

As of the reporting date, the sum total of all trial losses calculated on the basis of itemized measurement means that funds not exceeding the federal financial contributions for 2025–2028 were used. Seasonalized presentation of costs was taken into account.

Based on itemized measurement and the multi-year plan, an accrual/deferral to ensure the measurement of losses incurred by long-term projects was recognized as of the reporting date. This is reported in the balance sheet under accrued liabilities and deferred income and covers the full total of all individual losses on trials between 2024 and 2029 in accordance with SAKK's decentralized multi-year planning as at the end of January 2024.

The contributions from SERI for 2021 to 2024 were approved. The application for funding years 2025 to 2028 was submitted on schedule in 2023. SAKK is expecting a reply from SERI once the final decision from the parliamentary process has been made.

Other information

The negative financial market corrections from 2022 partially rectified themselves in 2023. The correction throughout the course of 2023 was positive overall. Nevertheless, the trend fluctuated, being characterized by gain phases and loss phases. SAKK regards the return to a lower rate of inflation and the first fall in key interest rates as an indicator that the trend is turning from a period of uncertainty about trends to a period of long-term positive financial market trends. This prompted the decision in summer 2023 to invest an additional CHF 4 million from liquid funds in the passive investment fund.

Auditor's Report



Balmer-Etienne AG Bern
 Schönburgstrasse 41
 Postfach 561
 3000 Bern 22
 Telefon +41 31 336 14 14
 info@roethlisbergerag.ch
 balmer-etienne.ch

Statutory Auditor's Report

to the General Assembly of

Swiss Group for Clinical Cancer Research SAKK, Berne

Report of the audit of the statutory financial statements

Opinion

We have audited the financial statements of Swiss Group for Clinical Cancer Research SAKK (the company), which comprise the balance sheet as at 31 December 2023, the income statement, the statement of cash flows, the statement of changes in equity, the statement of changes in funds for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the financial statements (pages 9 to 16) for the year ended 31 December 2023 comply with Swiss law and the company's articles of incorporation.

Basis for Opinion

We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Our responsibilities under those provisions and standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report.

We are independent of the company in accordance with the provisions of Swiss law and the requirements of the Swiss audit profession and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information in the Annual Report

The Board is responsible for the other information in the annual report. The other information comprises all information included in the annual report but does not include the financial statements and our auditor's reports thereon.

Our opinion on the financial statements does not cover the other information in the annual report and we do not express any form of assurance conclusion thereon.



In connection with our audit of the financial statements, our responsibility is to read the other information in the annual report and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibility of the Board for the financial statements

The Board is responsible for the preparation of the financial statements in accordance with the provisions of Swiss law and the company's articles of incorporation, and for such internal controls as the Board determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the auditing of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Swiss law and Swiss Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located at the website of EXPERTSuisse: <http://www.expertsuisse.ch/en/auditreport-for-public-companies>. This description forms part of our auditor's report.

Auditor's Report

Statutory Auditor's Report
Page 3/3 - Balmer-Etienne AG Bern - 13. May 2024



Report on other legal and statutory requirements

In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system exists, which has been designed for the preparation of financial statements according to the instructions of the Board.

We recommend that the financial statements submitted to you be approved.

Berne, 13 May 2024
1434 / 15042

Balmer-Etienne AG Bern

Fabrizio Conoscenti
Audit Expert
Authorised audit expert
Auditor in Charge

Elsa Reinhard
M A Business and Law, University of Berne
Auditor

Financial statements 2023

Publishing Details



Publisher and point of contact

Swiss Group
for Clinical Cancer Research SAKK
SAKK Competence Center
Effingerstrasse 33
3008 Bern
Switzerland

Phone +41 31 389 91 91
Media inquiries: media@sakk.ch
sakk.ch

SAKK donations account

IBAN: CH68 0900 0000 6029 5422 0
PostFinance AG, Mingerstrasse 20, 3030 Bern
BIC/SWIFT: POFICHBEXXX
Clearing no. (BLZ): 9000

Design, text and project management

Communications,
SAKK Competence Center
Georg Baumewerd
Konzept, Text and Workshops, Bern

Layout, typesetting and proofreading

Linkgroup AG, Zurich

Translations

BMP Translations AG, Basel

Printed by

Merkur Druck AG, Langenthal

About this report

The SAKK Financial Report for 2023 is available on our web-site at <https://www.sakk.ch/en/annual-report>

They are available in German, English and French.
The German version is authoritative.

Annual Portrait

The Financial Report is published as an addendum to the Annual Portrait. This reports on the events of 2023 and provides an insight into SAKK's activities.



Further information at
www.sakk.ch/en/annual-report

**Swiss Group
for Clinical Cancer Research SAKK**
Effingerstrasse 33, 3008 Bern, Switzerland
sakk.ch

